Study With Various Immunotherapy Treatments in Participants With Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 21, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
DRUG

Domvanalimab

Administered as specified in the treatment arm

DRUG

Quemliclustat

Administered as specified in the treatment arm

DRUG

Zimberelimab

Administered as specified in the treatment arm

DRUG

Docetaxel

Administered as specified in the treatment arm

DRUG

Platinum-Based Doublet

Administered as specified in the treatment arm

Trial Locations (51)

104

Mackey Memorial Hospital, Taipei

970

E-DA Healthcare Group E-DA Hospital, Kaoshiung

4217

Pindara Private Hospital, Benowa

5000

Cancer Research SA Pty Ltd, Adelaide

6009

Sir Charles Gairdner Hospital, Nedlands

8041

Hospital de la Santa Creu i Sant Pau, Barcelona

8221

Hospital Universitari Mutua Terrassa, Barcelona

23561

Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare, New Taipei City

28644

Chungbuk National University Hospital, Cheongju-si

32163

Florida Cancer Specialists (Administration and Drug Shipment), The Villages

33021

Memorial Cancer Institute at Memorial Regional Hospital, Hollywood

33604

CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque, Bordeaux

34952

Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie

35016

Complejo Hospitalario Universitario Insular Materno Infantil De Gran Canaria, Las Palmas de Gran Canaria

35128

Istituto Oncologico Veneto IRCCS, Padua

35294

University of Alabama at Birmingham (UAB), Birmingham

41001

Hospital Universitario De La Virgen De Valme, Seville

41009

Hospital Universitario Virgen Macarena, Seville

46015

Hospital 9 de Octubre Vithas Valencia, Valencia

46026

Hospital Universitario y Politécnico la Fe, Valencia

48202

Henry Ford Hospital, Detroit

58128

Chonam National University Hwasun Hospital, Hwasun-gun

60611

Northwestern Memorial Hospital, Chicago

67033

Institut De Cancerologie Strasbourg Europe ICANS, Strasboug

69495

Hospices Civils de Lyon Centre Hospitalier Lyon Sud, Lyon

70121

Ochsner Clinic Foundation, Jefferson

92093

University of California San Diego (UCSD), La Jolla

99208

Medical Oncology Associated, PS (dba Summit Cancer Centers), Spokane

Unknown

The Border Cancer Hospital, Albury

Hopital FOCH, Suresnes

LTD High Technology Hospital Medcenter, Batumi

Caucasus Medical Center, Tbilisi

Israel Georgian Medical Research Clinic Healthycore, Tbilisi

JSC K. Eristavi National Center of Experimental and Clinical Surgery, Tbilisi

Ltd Pineo Medical Ecosystem, Tbilisi

Istituto Romagnolo per lo Studio dei Tumori-Dino Amadori - IRST, Meldola

stituto Nazionale per lo Studio e la Cura dei Tumori, Milan

Azienda Sanitaria Territoriale Pesaro Urbino (AST PU), Pesaro

Fondazione IRCCS Istituto Nazionale dei tumori di Milano, Rome

Szpitale Pomorskie sp. z o.o, Gdynia

Uniwersyteckie Centrum Kliniczne, im. prof. K. Gibińskiego, Katowice

Medpolonia Sp. Z.o.o., Poznan

Centrum Onkologii - Instytut im. Marii Sk?odowskiej-Curie, Warsaw

Samsung Changwon Hospital, Changwon-Si

UOMI Cancer Centre, Barcelona

Hospital Universitario Lucus Augusti, Lugo

Hospital Quirónsalud Málaga, Málaga

National Taiwan University Hospital Yumlin Branch, Yunlin County

08308

Korea University Guro Hospital, Seoul

138-736

Asan Medical Center, Seoul

W1G 6AF

Barts Health NHS Trust St Bartholomew's Hospital, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Arcus Biosciences, Inc.

INDUSTRY

lead

Gilead Sciences

INDUSTRY

NCT05676931 - Study With Various Immunotherapy Treatments in Participants With Lung Cancer | Biotech Hunter | Biotech Hunter